Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul 28:6:100042.
doi: 10.1016/j.ijchy.2020.100042. eCollection 2020 Sep.

The effect of feedback on cardiovascular risk factors on optimization of primary prevention: The PharmLines initiative

Affiliations

The effect of feedback on cardiovascular risk factors on optimization of primary prevention: The PharmLines initiative

M Yldau van der Ende et al. Int J Cardiol Hypertens. .

Abstract

Background: It is unknown whether population based single assessment of cardiovascular disease (CVD) risk and feedback to individuals and general practitioners results in initiation of preventive cardiovascular pharmacotherapy in those at risk.

Methods: The population based cohort study Lifelines was linked to the IADB.nl pharmacy database to assess information on the initiation of preventive medication (N = 48,770). At the baseline visit, information on cardiovascular risk factors was collected and reported to the participants and their general practitioners. An interrupted-time-series-analysis was plotted, in which the start year of blood pressure and lipid lowering medication was displayed in years before or after the baseline visit. Subsequently, predictors of the initiation of pharmacotherapy were determined and possible reduction in cardiovascular events that could be achieved by optimal treatment of individuals at risk.

Results: Before the Lifelines baseline visit, 34% (out of 1,527, 95% Confidence interval (CI) 32%-36%) and 30% (out of 1,991, 95%CI 28%-32%) of the individuals at risk had a blood pressure or lipid lowering drug prescription, respectively. In those at risk, the use of blood pressure lowering medication, increased substantially during the year of the baseline visit. Treating individuals at increased risk (≥5% 10-year risk) with lipid or blood pressure lowering medication (N = 8515 and N = 6899) would have prevented 162 and 183 CVD events, respectively, in the upcoming five years.

Conclusion: Primary prevention of CVD in the general population appears suboptimal. Feedback of cardiovascular risk factors resulted in a substantial increase of blood pressure lowering medication and extrapolated health benefits.

Keywords: Cardiovascular disease; Lifelines; Primary prevention; Risk assessment; Risk factors.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Flowchart of the study population. N = number.
Fig. 2
Fig. 2
Interrupted time series analysis. On the Y-axis the percentages of treated individuals in whom treatment is recommended and the control group are displayed. On the X-axis the start year of preventive medication is displayed. The light blue vertical line is the year of the baseline visit. Continues lines represent the start of medication in individuals at risk. Dashed lines represent the start of medication in the control group (individuals without a recommendation for preventive medication). BL = baseline.

Similar articles

Cited by

References

    1. Timmis A., Townsend N., Gale C.P. European society of Cardiology: cardiovascular disease Statistics 2019. Eur. Heart J. 2020;41:12–85. - PubMed
    1. Cardoso R., Nasir K. Primary prevention of cardiovascular disease: 2019 and beyond. Nat. Rev. Cardiol. 2019;16:387–388. - PubMed
    1. Thomopoulos C., Parati G., Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials. J. Hypertens. 2014;32:2285–2295. - PubMed
    1. Blood Pressure Lowering Treatment Trialists' Collaboration Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet. 2014;384:591–598. - PubMed
    1. Simmons R.K., Griffin S.J., Witte D.R., Borch-Johnsen K., Lauritzen T., Sandbaek A. Effect of population screening for type 2 diabetes and cardiovascular risk factors on mortality rate and cardiovascular events: a controlled trial among 1,912,392 Danish adults. Diabetologia. 2017;60:2183–2191. - PMC - PubMed

LinkOut - more resources